Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Amortization of Deferred Charges (2024 - 2025)

TriSalus Life Sciences' Amortization of Deferred Charges history spans 2 years, with the latest figure at $249000.0 for Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges rose 9.69% year-over-year to $249000.0; the TTM value through Dec 2025 reached $1.4 million, up 69.76%, while the annual FY2025 figure was $1.0 million, 73.68% up from the prior year.
  • Amortization of Deferred Charges reached $249000.0 in Q4 2025 per TLSIW's latest filing, up from $200000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $766000.0 in Q2 2025 to a low of $177000.0 in Q1 2025.